SCHEMBL19970086

SCHEMBL19970086

Cc1ccc(Cl)cc1-c1nc(NSc2cccc(N3CCC[C@@](C)(C(=O)O)C3)n2)ccc1C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.37
KCNH2 Q12809 1/20 0.37
BTK Q06187 2/20 0.34
CNR1 P21554 2/20 0.34
CNR2 P34972 1/20 0.34
BRAF P15056 5/20 0.32
EIF2AK4 Q9P2K8 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
RAF1 P04049 4/20 0.31
HCRTR1 O43613 2/20 0.31
HCRTR2 O43614 2/20 0.31
RBP4 P02753 1/20 0.31
TTR P02766 1/20 0.31
FAAH O00519 2/20 0.31
RORC P51449 1/20 0.31
KRAS P01116 1/20 0.31
MGLL Q99685 1/20 0.31
S1PR1 P21453 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770463 0.92 BTK (0.34) DGAT1KCNH2BTKBRAFEIF2AK4
SCHEMBL19970118 0.91 RORC (0.35) DGAT1KCNH2CNR1CNR2BRAF
SCHEMBL23770834 0.91 DGAT1 (0.36) DGAT1KCNH2BTKCNR1CNR2
SCHEMBL23770470 0.89 DGAT1 (0.35) DGAT1KCNH2BTKCNR1CNR2
SCHEMBL19970083 0.88 BTK (0.34) DGAT1KCNH2BTKCNR2BRAF
SCHEMBL23770875 0.88 BTK (0.34) DGAT1KCNH2BTKCNR2BRAF
SCHEMBL19970089 0.87 BTK (0.36) DGAT1KCNH2BTKEIF2AK4RBP4
SCHEMBL23770459 0.86 BTK (0.34) BTKEIF2AK4HCRTR1HCRTR2RORC
SCHEMBL23770832 0.86 RBP4 (0.33) BTKRBP4TTRRORC
SCHEMBL23770734 0.85 HCRTR1 (0.35) DGAT1KCNH2BTKCNR1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 US disclosed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 DGAT1 4612/4885KCNH2 324/4885BTK 235/4885
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 DGAT1 4612/4885KCNH2 324/4885BTK 235/4885
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 DGAT1 4612/4885KCNH2 324/4885BTK 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.